Monte Rosa Therapeutics Q3 2024 Earnings Report

Monte Rosa Therapeutics EPS Results

• Actual EPS: -$0.29
• Consensus EPS: -$0.45
• Beat/Miss: Beat by +$0.16
• One Year Ago EPS: N/A

Monte Rosa Therapeutics Revenue Results

• Actual Revenue: $9.22 million
• Expected Revenue: $4.54 million
• Beat/Miss: Beat by +$4.68 million
• YoY Revenue Growth: N/A

Monte Rosa Therapeutics Announcement Details

• Quarter: Q3 2024
• Date: 11/7/2024
• Time: N/A
• Conference Call Date: Thursday, November 7, 2024
• Conference Call Time: 7:00AM ET

Monte Rosa Therapeutics (NASDAQ:GLUE) is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience. In immuno-oncology, Monte Rosa applies its platform to better understand tumor microenvironments and to design molecules that modulate immune cell activity. In neuroscience, the company focuses on identifying targets implicated in neurodegenerative and neuroinflammatory disorders. Through this dual therapeutic focus, Monte Rosa seeks to advance candidates from early discovery through lead optimization and into partnerships or further development stages.

Monte Rosa operates at the intersection of technology and biology, collaborating with academic institutions and industry partners to validate its discoveries and expand its library of therapeutic assets. The company is led by a team of experienced executives and scientists with backgrounds in genomics, AI, drug development and venture financing. While primarily based in the United States, Monte Rosa’s platform and partnerships enable it to engage with global research networks and to pursue programs with worldwide impact.